A 47-year-old Chinese female patient presented with a two-year history of erythematous plaques over the face, axillae and abdomen. Two biopsies were performed before the diagnosis of primary cutaneous marginal zone B-cell lymphoma was made. No evidence of systemic involvement was present at the time of diagnosis. She was subsequently commenced on cyclical chlorambucil.
Introduction
Primary cutaneous marginal zone B -cell lymphoma (PCMZL) is classified under the 'cutaneous B-cell lymphoma' in the latest WHO-EORTC classification for cutaneous lymphoma. 1 It is a low grade B-cell lymphoma in which systemic spread is rare. Diagnosis is based on consistent clinical features, histopathology, immunological profile and cytogenesis studies. The condition has an excellent prognosis with a 90-100% 5-year survival. 2 
Case report
A 47-year-old female patient presented with a two-year history of multiple erythematous plaques over her face, axillae and abdomen which were occasionally pruritic (Figures 1 & 2) . There was no associated photosensitivity. She had no systemic symptoms, including fever, weight loss, joint pain or alopecia. Her travel, drug and past medical histories were unremarkable. She was a non-smoker and non-drinker who worked on construction sites. no nail changes, lymphoadenopathy or hepatosplenomegaly. Examination of other systems were unremarkable. The main clinical differential diagnoses included discoid lupus erythematosus, lupus erythematosus tumidus, Jessner's lymphocytic infiltration of the skin, lymphocytoma cutis, cutaneous lymphoma and lupus vulgaris.
Blood tests including complete blood picture, renal and liver function tests were within normal limits. ESR was mildly raised at 24 mm/1 hr. Anti-nuclear antibody was negative.
An incisional skin biopsy was performed over the forehead. It showed non-specific changes of perivascular lymphocytic infiltration with a rich plasma cell component, which would be consistent with connective tissue disease. The patient was put on a trial of topical 1% hydrocortisone cream, and later 0.1% mometasone furoate cream, without improvement. A second biopsy was performed over the left axillary plaque (Figures 3 & 4) . It showed dense, demarcated, lymphoplasmacytic infiltrates around blood vessels and skin appendages in the dermis. The infiltrates included centrocyte-like cells. Follicle formation was present. The epidermis was unremarkable and dermal mucin was not increased. PCR for immunoglobulin Fr3/JH gene rearrangement was demonstrated, which suggested monoclonal B-cell proliferation. The overall morphology was consistent with cutaneous marginal zone B-cell lymphoma. The patient was referred to the medical team for workup of any systemic involvement. Bone marrow examination and CT imaging showed no extracutaneous involvement. The diagnosis of primary cutaneous marginal zone B-cell lymphoma (WHO-EORTC) was made. The patient was commenced on cyclical chlorambucil 10 mg daily for 2 weeks.
Discussion
PCMZL is a low grade B-cell lymphoma which is Physical examination showed multiple non-tender, fairly well-defined, roundish erythematous nodules and plaques over the forehead, temporal region and cheek. Telangiectasia was noted over some of the lesions, but there was no ulceration, scaling, follicular plugging or atrophy. Diascopy was negative. Similar, but smaller, lesions were present over the abdomen and right thigh. Several brown linear plaques were identified over both axillae. Her extremities and back were spared. There were Classification (WHO), it is equivalent to 'extranodal marginal zone B-cell lymphoma of mucosaassociated lymphoma tissue (MALT lymphoma)'. The latest WHO-EORTC classification for cutaneous lymphoma uses the term 'primary cutaneous marginal zone B-cell lymphoma' to unify the various entities above when they occur primarily in the skin. The pathogenesis of PCMZL is not fully understood. Borrelia burgdoferi is associated with a significant minority of the European cases, 3 but it has not been reported in any Asian 4 or US 5 cases. It is postulated that PCMZL arises from chronically stimulated lymphoid tissue acquired in the skin in response to B. burgdoferi infection. This phenomenon is analogous to H. pylori infection in gastric MALT lymphoma. Clinically, PCMZL are typically found over the trunk, upper limbs, chest, axillary folds and back. The head and neck regions are less commonly involved. The lesions are red to violaceous papules, nodules or plaques. Ulceration is uncommon. Multifocal lesions are often present at the time of diagnosis. PCMZL tends to recur in skin, but dissemination to extracutaneous sites is rare. However, it is necessary to look for extracutaneous involvement when the diagnosis is initially made, especially of the gastrointestinal Reactive germinal centres are also frequently identified. The epidermis is usually uninvolved. Histologically, PCMZL needs to be differentiated from primary cutaneous follicle centre lymphoma, cutaneous pseudolymphoma, and non-Hodgkin's B-cell lymphoma with secondary involvement of the skin. This differentiation is not always easy, and can be assisted by immunoprofile and cytogenetic studies. In PCMZL, the marginal zone B-cells express CD19, CD20, CD22, CD79a and bcl-2. They are negative for CD5, CD10, bcl-6 and CD23. The lymphoplasmacytoid cells and plasma cells show monotypic expression of Ig light chains (K/λ) on paraffin sections. Cytogenetic studies show clonal rearrangement of the immunoglobulin heavy chain (IgH) genes. Recent studies suggest the presence of the t(14;18)(q32;q21) involving the IGH gene on chromosome 14 and the MLT gene on chromosome 18, and t(3;14)(p14.1;q32) involving IGH and FOXP1 genes, in a proportion of PCMZLs. 6, 7 The most appropriate therapy for PCMZL has not been established. The management depends on whether the lesion is solitary or multifocal, and whether the disease is at its initial presentation or recurrence. If only a few lesions are present, the choices include radiotherapy or surgical excision. However, there is a high rate of local relapse for patients receiving only local therapy. Therefore, some argue that systemic or combined modality therapies may be preferable to local therapy. Systemic therapies are also used for more extensive multifocal lesions. They include chemotherapy (chlorambucil, 8 cyclophosphomide, doxorubicin, vincristine and prednisolone), anti-CD20 antibody (Rituximab) 9 and interferon α-2a.
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In recurrence, a wait-and-see strategy can be adopted since the disease has a low mortality. Nevertheless, palliative treatment (e.g. radiotherapy) can be used for larger or disturbing skin lesions. It is also worth noting that a trial of systemic antibiotics for possible B. burgdoferi infection in endemic regions can be considered. Overall, as PCMZL is a relatively indolent lymphoma, the benefits of treatment should be weighed against any possible side-effects.
The prognosis is PCMZL is excellent with a 90-100% 5-year survival. Spontaneous resolution of skin lesions have been reported in some cases. Complete remission is usually achieved after initial treatment, but relapse and local recurrence is seen in 30-48% of cases.
